There are well described constellations of symptoms following the withdrawal of ethanol,1 -7 barbiturates8
- 13 and benzodiazepines, 26 summarised in table 1 .
There have been few investigations of possible withdrawal syndromes after cessation of nonbarbiturate antiepileptic drugs (AEDs). Thirty eight patients took 200 to 400 mg phenytoin daily for 1 to 8 months, stopped the drug abruptly and no withdrawal symptoms were noted.27 28 DemersDesrosiers et a129 reported two epileptic patients, with no previous history of psychosis, who became psychotic a day after withdrawal of AEDs. Both patients were taking barbiturates as well as phenytoin, and carbamazepine in one, so it is not possible to ascribe the symptoms to withdrawal of either phenytoin or carbamazepine.29 Carbamazepine is structurally similar to the tricyclic antidepressants and there are reports of symptoms following withdrawal of these agents (table 1) .3°- 39 We report a prospective, placebo-controlled, double-blind study to determine the occurrence of withdrawal symptoms following the reduction and discontinuation of carbamazepine, phenytoin and sodium valproate, in patients with active epilepsy, with each drug being reduced at one of two rates. The effect of these drug changes on seizures is considered in a separate paper (Duncan et al, in preparation).
Ninety five patients were studied, including a control group of 25 patients who remained on stable therapy. All had active epilepsy, were taking two or more AEDs, and were Overall, there were no significant differences in the numbers of patients developing symptoms and signs in the fast and slow streams of AED reduction (table 4). In the four separate AED groups, the slow control group had a greater incidence of new tremor, on examination, than did the fast controls (chi2 = 4-42, 1 DF, p = 0 03, OR = 19 8, 1-409). No symptoms or signs developed in the three drug reduction groups with an incidence that was significantly different from the control group.
There was no significant difference between the numbers of patients with an increase in rating scale scores in the fast and slow streams, or when the three active reduction groups were compared with the controls (table 4). Friedman's test for each symptom rating scale, on the fast and slow streams of each AED group, was non-significant with the exception of shaking in the carbamazepine slow group (chi2 = 10-9, 5 Duncan, Shorvon, Trimble Total patient numbers   10   12   0  3  2  4  2  1  0  2  3  2  2  1  2  3  4  5  2  1  3  1  4  3  1  1   0   0  3  4  0  1  1  0  1  2  0  0  2  0  3  2  0  0  13  10  14  1 1  13 In this study, there was no convincing evidence for the development of a withdrawal syndrome, following the reduction and cessation of treatment with these drugs. There was no significant change in seizure numbers in the phenytoin, sodium valproate or control
groups. Seizures increased on carbamazepine reduction and this increase was maintained through the 4 weeks after withdrawal (Duncan et al, in preparation). The two patients who were noted to have a change in affect after withdrawal of carbamazepine both had a marked increase in seizures at this time, so it is not possible to ascribe these changes directly to the withdrawal of the drug, rather than to a post-ictal effect.
Several possible reasons for the absence of an identifiable withdrawal syndrome in this study need consideration. The size of the patient groups was relatively small. The patient groups were well matched for important variables, the minor differences in age are not likely to have influenced the results. AED reduction was gradual, over 1 to 7 weeks, baseline drug levels were not high, and all patients were also taking at least one other AED. Further, there was a low prevalence of psychiatric disturbance (13/95) in the subjects of this investigation, compared with most studies of the withdrawal of sedative drugs, and patients with such problems may be more likely to note symptoms. The assessment of possible withdrawal symptoms was made weekly; it is possible that minor, transient symptoms were not noted by the patients, but it is not likely that any significant reactions were overlooked. The assessment schedule was deliberately simple; it is conceivable that a more sophisticated enquiry may have yielded positive results. The statistical analysis, however, was sensitive and was designed to identify both numbers of patients who had new symptoms and a significant increase in rating scales, and also to detect more subtle underlying changes in scores.
Phenytoin, carbamazepine and sodium valproate are relatively non-sedating and do not have the acute, intense, habit-forming psychotropic effects that are associated with barbiturates, benzodiazepines and alcohol, and this may explain why there were no rebound effects following withdrawal of these AEDs. However, carbamazepine and sodium valproate have been noted to ameliorate the symptoms of the alcohol withdrawal syndrome44546 and carbamazepine has been claimed to minimise the effects of alprazolam withdrawal.47 If verified, these findings would indicate that there may be some cross-tolerance between sedative drugs and carbamazepine and sodium valproate.
Carbamazepine has a similar structure to tricyclic antidepressants, and there is a well defined tricyclic withdrawal syndrome. Most features of this syndrome, however, respond to atropine, suggesting that they are the result of cholinergic supersensitivity, and carbamazepine has some anticholinergic activity.48 In the current investigation, there was no convincing evidence of a "tricyclic withdrawal syndrome" following removal of carbamazepine.
In conclusion, it does not seem likely that a significant withdrawal syndrome could have developed in these patients and not been noted. A likely explanation of the negative result is that withdrawal of phenytoin, carbamazepine and sodium valproate at these rates, in patients who are remaining on one or more other AEDs, is not associated with any significant withdrawal symptoms, other than seizures. It appears improbable that withdrawal symptoms are likely to be a clinical problem, when these AEDs are discontinued in clinical practice. 
